# Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Source: https://onco.cc/trials/nct06393374/  
OnCo record `nct06393374` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pembrolizumab, Sacituzumab tirumotecan and Capecitabine in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) is a phase 3 interventional study registered as NCT06393374 by Merck Sharp & Dohme LLC, with 1530 participants planned, started 2024-06-24 and due to reach its primary completion in 2030-12-16. Interventions recorded: Pembrolizumab, Sacituzumab tirumotecan and Capecitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06393374
- Phase: 3
- Setting: A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 1530

## Sources

- ClinicalTrials.gov NCT06393374: https://clinicaltrials.gov/study/NCT06393374

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06393374.json